IRLAB THERAPEUTICS AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.85 SEK | 0.00% |
|
+6.38% | +111.33% |
| 07-10 | Transcript : IRLAB Therapeutics AB, H1 2024 Earnings Call, Jul 10, 2024 | |
| 07-10 | IRLAB Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 | CI |
Presenter SpeechMattias Vahlne (Attendees)In today's broadcast with research company, IRLAB fo...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinsonâs disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinsonâs Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).
Sector
Pharmaceuticals
Calendar
25/10/2024
- Q3 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +111.33% | 77.69M | |
| +63.05% | 856B | |
| +39.12% | 631B | |
| -4.78% | 359B | |
| +17.52% | 325B | |
| +8.43% | 297B | |
| +13.53% | 244B | |
| +5.44% | 234B | |
| +16.45% | 226B | |
| +14.63% | 177B |
- Stock Market
- Equities
- IRLAB A Stock
- News IRLAB Therapeutics AB
- Transcript : IRLAB Therapeutics AB, H1 2024 Earnings Call, Jul 10, 2024
